SCHEMBL956866

SCHEMBL956866

Fc1ccc(Cn2ccc3c(Cl)ccnc32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.56
FGFR4 P22455 1/20 0.56
HRH3 Q9Y5N1 2/20 0.45
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
SRC P12931 7/20 0.43
FLT3 P36888 5/20 0.43
FYN P06241 5/20 0.43
DBH P09172 1/20 0.42
PDE4A P27815 1/20 0.42
PDE4B Q07343 1/20 0.42
PDE4C Q08493 1/20 0.42
PDE4D Q08499 1/20 0.42
TP53 P04637 1/20 0.41
ABL1 P00519 1/20 0.41
CYP19A1 P11511 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19730198 0.84 FGFR1 (0.49) FGFR1FGFR4ALDH1A1SCN9A
SCHEMBL16888474 0.81 ABL1 (0.49) FGFR1FGFR4LMNAMAPTTHRB
SCHEMBL29246282 0.79 FGFR1 (0.56) FGFR1FGFR4HRH3MAPTTHRB
SCHEMBL30910343 0.79 FGFR1 (0.56) FGFR1FGFR4HRH3MAPTTHRB
SCHEMBL957705 0.76 SMN1; SMN2 (0.52) LMNASMN1; SMN2MAPTTHRBDBH
SCHEMBL9278020 0.74 TP53 (0.45) LMNASMN1; SMN2MAPTSRCFLT3
SCHEMBL2038788 0.72 FGFR1 (0.39) FGFR1FGFR4SMN1; SMN2ALDH1A1
SCHEMBL31240654 0.72 FGFR1 (0.39) FGFR1FGFR4SMN1; SMN2ALDH1A1
SCHEMBL6085877 0.72 HTR6 (0.53) LMNASMN1; SMN2MAPTTHRBDBH
SCHEMBL22533570 0.71 FGFR1 (0.44) FGFR1FGFR4HRH3LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450343-B2 Gamma secretase modulators SCHERING CORPORATION 2013-05-28 US disclosed
US-8450343-B2 Gamma secretase modulators SCHERING CORPORATION 2013-05-28 US disclosed
US-8450343-B2 Gamma secretase modulators SCHERING CORPORATION 2013-05-28 US disclosed
US-20110015190-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-20 US disclosed
US-20110015190-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-20 US disclosed
US-20110015190-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION 2011-01-20 US disclosed
CN-101939315-A Gamma secretase modulators SCHERING CORP 2011-01-05 CN disclosed
EP-2229381-A1 GAMMA SECRETASE MODULATORS Schering Corporation (US) 2010-09-22 EP disclosed
WO-2009073777-A1 GAMMA SECRETASE MODULATORS SCHERING CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015190-A1 GAMMA SECRETASE MODULATORS BACE1, BACE2, PSEN1 FGFR1 2737/4885FGFR4 2900/4885HRH3 2095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.